These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22385406)

  • 21. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V; Knopf KB; Norris LB; Chen B; Yang YT; Qureshi ZP; Hrushesky W; Lebby AA; Schooley B; Hikmet N; Dickson M; Thamer M; Cotter D; Yarnold PR; Bennett CL
    J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.
    Minutolo R; Borzumati M; Sposini S; Abaterusso C; Carraro G; Santoboni A; Mura C; Filiberti O; Santoro D; Musacchio R; Imperiali P; Fiorini F; De Nicola L; Russo D
    Am J Kidney Dis; 2016 Jul; 68(1):170-2. PubMed ID: 26879099
    [No Abstract]   [Full Text] [Related]  

  • 28. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Cremieux PY; Van Audenrode M; Lefebvre P
    Curr Med Res Opin; 2006 Dec; 22(12):2329-36. PubMed ID: 17257447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.
    Perrone V; Saragoni S; Buda S; Broccoli A; Degli Esposti L
    Biologics; 2016; 10():157-165. PubMed ID: 27942203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study.
    Stoppa G; D'Amore C; Conforti A; Traversa G; Venegoni M; Taglialatela M; Leone R;
    BioDrugs; 2018 Aug; 32(4):367-375. PubMed ID: 30030767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
    Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
    Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S; Plavljanić E; Trkulja V
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application.
    Okano M; Sato M; Kaneko E; Kageyama S
    Drug Test Anal; 2011; 3(11-12):798-805. PubMed ID: 22012825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
    Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
    Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.